Trendlines project receives up to US$0.2 mil grant from SIIRD

SINGAPORE (March 29): The Trendlines Group’s business unit Trendlines Labs, In partnership with the Singapore General Hospital (SGH), will receive a grant of up to US$0.2 million ($0.3 million) for the development and clinical trial for its Stress Urinary Incontinence (SUI) product.

The grant is provided by the Singapore Israel Industrial Research and Development Foundation (SIIRD).

SIIRD is a co-operation between the two countries which aims to promote, facilitate and support joint industrial research and development (R&D) projects.

---

Related Stories

• Trendlines expects US$25 mil to US$30 mil loss for FY2023 in profit warning
• Trendlines is impacted by Hamas invasion, company says
• Trendlines to report a loss for 1HFY2022 with US$7.9 mil portfolio company write-off

---